drugset / Trial / NCT01872026

Examination of Plasma Concentrations and Safety in Chronic Kidney Disease Patients Undergoing Hemodialysis

NCT01872026

Phase 1 Completed 14 enrolled Astellas Pharma Inc
Non-randomizedParallel-groupOpen-labelOther

Summary

This study is to assess the safety, tolerability, plasma concentration and pharmacodynamics of ASP7991 after oral administration to patients with chronic kidney disease undergoing hemodialysis.

Timeline

Start
2012-12-26
Primary completion
2013-06-26
Completion
2013-06-26

Drugs

EvaluationDrugModalityDoseRoute
Subject ASP7991 Unknown Oral

Indications

No indication recorded.